MedPath

Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial

Not Applicable
Recruiting
Conditions
Coronary Disease
Ischemic Heart Disease
Coronary Artery Disease
Interventions
Other: FFR>0.80+ OCT with findings indicative of vulnerable plaque
Registration Number
NCT05599061
Lead Sponsor
Fundación EPIC
Brief Summary

The study aims to compare a preventive percutaneous coronary intervention (PCI) plus optimal medical treatment (OMT) strategy vs. OMT for treatment of non-functionally significant non-culprit lesions presenting with optical coherence tomography (OCT) findings indicative of vulnerable plaque, in patients with ST-elevation myocardial infarction (STEMI) and multivessel disease.

Detailed Description

STEMI patients with multivessel disease planned for invasive evaluation of intermediate lesions (40-69% stenosis) are initially investigated with fractional flow reserve (FFR). Patients with FFR ≤ 0.80 are considered as screening failure and treated with PCI. Patients with FFR \> 0.80 are then investigated with optical coherence tomography (OCT). Patients without OCT findings of vulnerable plaque are treated with OMT and included in the OMT registry arm. Patients presenting with OCT characteristics of vulnerable plaque are included in the randomized trial comparing PCI with stent implantation plus OMT versus OMT.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
600
Inclusion Criteria
  • Patients > 18 years.
  • Successful revascularization of the culprit lesion in patients undergoing coronary angiography due to ST-segment elevation (> 1mm in > 2 contiguous leads, new left bundle branch block, or true posterior MI with ST depression of >1mm in >2 contiguous anterior leads) in the first 72 hours of the symptom's onset.
  • Multivessel coronary disease with non-culprit lesions located in different vessels than the culprit lesion and ranging from 40 to 69% of DS (visual estimated diameter stenosis ) by visual estimate planned for FFR-guided revascularization in staged procedure (>24 hours and <60 days after PCI of the culprit lesion).
  • Non-culprit lesions should be suitable for functional assessment with pressure wire and OCT catheter and should be suitable to be treated with a single 2.0 to 4.5 mm EES (everolimus-eluting stent ).
  • Subject agrees to not participate in any other clinical trial study for a period of 4 years following the inclusion in the study.
  • Informed consent signed.
Exclusion Criteria
  • Inability to provide informed consent.
  • Female of childbearing potential (age <50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy.
  • Known intolerance to aspirin, heparin, everolimus, contrast material.
  • Unresolved mechanical complication or cardiogenic shock at the staged procedure.
  • Non-culprit study lesions located in the left main coronary artery or in coronary vessels with prior coronary revascularization (PCI or by-pass) or with distal vessel occlusion.
  • Patients with long, bifurcated, severely angulated or severely calcified non-culprit study lesions non suitable to be treated with a single EES implantation.
  • Asthma or known history of bronchial hyper-reactivity.
  • Chronic renal dysfunction with creatinine clearance < 45 ml/min.
  • Severe comorbidities that in the opinion of the local investigators determine the patient's life expectancy < 4 years.
  • Subject is currently participating in another clinical trial that has not yet completed its primary endpoint.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Optimal Medical Treatment (OMT) + PCIFFR>0.80+ OCT with findings indicative of vulnerable plaque-
Optimal Medical Treatment (OMT)FFR>0.80+ OCT with findings indicative of vulnerable plaque-
Primary Outcome Measures
NameTimeMethod
Target Vessel Failure (TVF)4 Years

TVF as a composite of :

Cardiovascular Death Target-vessel related MI Clinically and physiologically-oriented Target vessel revascularization

Secondary Outcome Measures
NameTimeMethod
Cardiac death4 Years

To compare Cardiac death between both groups in the randomized arm death.

All Myocardial Infarctions4 Years

To compare Myocardial Infarctions between both groups in the randomized arm death. death

Target-Vessel Myocardial Infarction4 Years

To compare target-vessel myocardial infarction between both groups in the randomized arm.

Minimal lumen area by Optical Coherence Tomography (OCT)4 years

To establish the optimal OCT-derived minimal lumen area cutoff to predict an ischemic FFR in the non-culprit artery in the acute setting.

Revascularizations4 Years

To compare all revascularizations between both groups in the randomized arm.

Patient-oriented endpoint of major adverse cardiac events4 Years

To compare the patient-oriented endpoint of major adverse cardiac events, a composite of all-cause death, myocardial infarction, and revascularization between both groups in the randomized arm.

Fractional Flow Reserve (FFR)4 years

To compare the FFR values between patients with vulnerable plaques (randomized arm) and patients without vulnerable plaques (OMT registry).

Target Vessel Failure (TVF)4 Years

To compare the TVF rate between patients included in the OMT group of the randomized arm (presenting with vulnerable plaque) vs. patients included in the OMT registry (without vulnerable plaque).

Accuracy of vulnerable plaque assessment by Optical Coherence Tomography (OCT)4 years

To compare the agreement between local operators and the core-laboratory to assess vulnerable plaques by OCT.

All-cause Death4 Years

To compare all death between both groups in the randomized arm death.

Ischemic-driven target vessel revascularization4 Years

To compare ischemic-driven target vessel revascularization between both groups in the randomized arm.

Trial Locations

Locations (44)

Hospital Universitari de Bellvitge

🇪🇸

Hospitalet de Llobregat, Spain

Hospital General Universitario de Albacete

🇪🇸

Albacete, Spain

Hospital General Universitario Dr.Balmis

🇪🇸

Alicante, Spain

Hospital Universitari Sant Joan D'Alacant

🇪🇸

Alicante, Spain

Hospital Universitari Germans Trias I Pujol

🇪🇸

Badalona, Spain

Hospital Del Mar

🇪🇸

Barcelona, Spain

Hospital de Santa Creu I Sant Pau

🇪🇸

Barcelona, Spain

Hospital Universitari Vall Hebron

🇪🇸

Barcelona, Spain

Hospital Clinic de Barcelona

🇪🇸

Barcelona, Spain

Hospital Universitario Puerta Del Mar

🇪🇸

Cadiz, Spain

Hospital General Universitario de Castellón

🇪🇸

Castellón De La Plana, Spain

Hospital General Universitario de Ciudad Real

🇪🇸

Ciudad Real, Spain

Hospital Universitario A Coruña

🇪🇸

Coruña, Spain

Hospital Universitario Reina Sofia de Cordoba

🇪🇸

Córdoba, Spain

Hospital General Universitario de Elche

🇪🇸

Elche, Spain

Hospital Universitario de Cabueñes

🇪🇸

Gijón, Spain

Hospital Universitario de Girona Dr Trueta

🇪🇸

Girona, Spain

Hospital Universitario San Cecilio

🇪🇸

Granada, Spain

Hospital Universitario Juan Ramon Jimenez

🇪🇸

Huelva, Spain

Hospital Universitario de Leon

🇪🇸

León, Spain

Hospital La Princesa

🇪🇸

Madrid, Spain

Hospital Universitario Gregorio Marañon

🇪🇸

Madrid, Spain

Hospital Universitario La Paz

🇪🇸

Madrid, Spain

Hospital Universitario Puerta de Hierro

🇪🇸

Majadahonda, Spain

Hospital de Manises

🇪🇸

Manises, Spain

Hospital Universitario Virgen Arrixaca

🇪🇸

Murcia, Spain

Hospital Universitario Central de Asturias

🇪🇸

Oviedo, Spain

Hospital Universitari Son Espases

🇪🇸

Palma De Mallorca, Spain

Hospital Universitario de Navarra

🇪🇸

Pamplona, Spain

Hospital Clinico Universitario de Salamanca

🇪🇸

Salamanca, Spain

Hospital Universitario de Donostia

🇪🇸

San Sebastián, Spain

Hospital Universitario Marqués de Valdecilla

🇪🇸

Santander, Spain

Hospital Clinico Universitario de Santiago de Compostela

🇪🇸

Santiago De Compostela, Spain

Hospital Universitario Virgen Del Rocio

🇪🇸

Sevilla, Spain

Hospital Universitari Joan Xxiii

🇪🇸

Tarragona, Spain

Hospital Universitario Nuestra Señora de La Candelaria

🇪🇸

Tenerife, Spain

Hospital Universitario de Torrevieja

🇪🇸

Torrevieja, Spain

Hospital Universitario 12 Octubre

🇪🇸

Usera, Spain

Hospital Clinico Universitario de Valencia

🇪🇸

Valencia, Spain

Hospital General Universitario de Valencia

🇪🇸

Valencia, Spain

Hospital Universitari I Politecnic La Fe

🇪🇸

Valencia, Spain

Hospital Clínico Universitario de Valladolid

🇪🇸

Valladolid, Spain

Hospital Clinico Universitario Lozano Blesa

🇪🇸

Zaragoza, Spain

Hospital Universitari Miquel Servet

🇪🇸

Zaragoza, Spain

© Copyright 2025. All Rights Reserved by MedPath